CN103861086A - Preparation method of bitter gourd peptide arabinose composite tablet - Google Patents
Preparation method of bitter gourd peptide arabinose composite tablet Download PDFInfo
- Publication number
- CN103861086A CN103861086A CN201410082006.8A CN201410082006A CN103861086A CN 103861086 A CN103861086 A CN 103861086A CN 201410082006 A CN201410082006 A CN 201410082006A CN 103861086 A CN103861086 A CN 103861086A
- Authority
- CN
- China
- Prior art keywords
- parts
- arabinose
- bitter gourd
- inulin
- dimensional mixer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention relates to a preparation method of a bitter gourd peptide arabinose composite tablet. The bitter gourd peptide arabinose composite tablet consists of the following components in parts by weight: 8-15 parts of bitter gourd polypeptides, 15-25 parts of L-arabinose, 0.1-0.3 part of chromium-enriched yeast, 25-35 parts of inulin, 5-15 parts of phytosterol, 10-15 parts of D- mannitol, 10-20 parts of microcrystalline cellulose, 0.5-1 part of magnesium stearate, and 2-5 parts of hydroxypropyl methylcellulose. The preparation method has beneficial effects that the bitter gourd peptide arabinose composite tablet is prepared by adopting a plurality of components beneficial to blood sugar control and blood lipid metabolism; compared with a way of independently adopting the bitter gourd polypeptides, the inulin or the phytosterol, and the like, a way of combining the bitter gourd polypeptides, the inulin or the phytosterol, and the like is better in effect, beneficial to blood sugar control and blood lipid metabolism of a patient with diabetes mellitus II, and free of influences on functions of livers and kidneys. Besides, the preparation method can improve sensibility of insulin better and can remarkably lower total cholesterol and low-density lipoprotein cholesterol of the patient with diabetes mellitus II.
Description
Technical field
The present invention relates to a kind of preparation method of arabinose composite sheet, particularly a kind of manufacture method of Fructus Momordicae charantiae peptide arabinose composite sheet.
Background technology
Diabetes are a kind of global epidemic diseases, have become the chronic disease of the third-largest serious threat human health after tumor, cardiovascular disease.Estimate according to WHO, the existing diabetics in the whole world 1.75 hundred million left and right, will reach 300,000,000 to 2025 at present.China has become the fastest-rising area of diabetics in global range, has increased 4-5 doubly from the eighties to the mid-90 in 20th century.According to incompletely statistics, the at present existing diabetics three or four thousand ten thousand of China; And in the diabetes main forces that increase progressively every day, type Ⅱdiabetes mellitus proportion is up to more than 90%.The principal element that causes II diabetics significantly to increase is the huge change of dietary structure in recent years.The medicine of diabetes is of a great variety, but for diabetics, tonic is also to control the important step of disease development.
Chinese patent literature number is 102302119A, patent name is " a kind of L-arabinose chewable tablet and preparation method thereof ", and this chewable tablet is to be prepared from by the raw material of following weight portion proportioning: 20～50 parts of L-arabinose, 10～60 parts of defatted milk powder, 0.5～1.5 part of edible pollen, 0～30 part of Semen Armeniacae Amarum powder, 0.1～1 part of compound vitamin, 0.1～0.5 part of magnesium stearate, 0.1～2.0 part of sodium carboxymethyl cellulose.Compared to the prior art L-arabinose chewable tablet of the present invention, has balanced in nutrition, green health, strong mellow, the pure and fresh gracefulness of mouthfeel, the feature such as light and handy portable, and being applicable to very much diabetes, coronary heart disease, hypertension, hyperlipidemia etc., to prohibit sucrose crowd edible.
Chinese patent literature number is 101810263A, and patent name is " compound biological sugar ", and its primary raw material is L-arabinose, functional oligose and dietary fiber, and its percentage by weight is respectively 30-70%, 5-20% and 20-70%; Batching is binding agent, banana aldehyde and sour powder, and their percentage by weight is 0.1-2%, 0.1-2% and 0.1-10% respectively.At the enzyme of human body intestinal canal inner shield decomposing sucrose, make human body cannot absorb sucrose; This compound biological sugar produces organic acid after arriving large intestine, suppresses liver depot fat, thereby suppresses athero; In intestinal, set up excellent micro-ecological environment, help probiotics growth, prevent constipation, discharge toxin.
But above-mentioned prior art does not add inulin, bitter gourd polypeptide, plant sterol etc. in glycoconjugates simultaneously.
Summary of the invention
Object of the present invention is exactly in view of the foregoing defects the prior art has, a kind of manufacture method of Fructus Momordicae charantiae peptide arabinose composite sheet is provided, after its combination, effect is better, insulin sensitivity can be more improved, and T-CHOL and the low-density lipoprotein cholesterol of patients with NIDDM can be significantly reduced.
The manufacture method of the Fructus Momordicae charantiae peptide arabinose composite sheet that the present invention mentions is made up of following component, each component is according to listed as parts by weight: 8 ~ 15 parts of bitter gourd polypeptides, 15 ~ 25 parts of L-arabinose, 0.1 ~ 0.3 part of Rich chromium yeast, 25 ~ 35 parts of inulin, 5 ~ 15 parts of plant sterols, 10 ~ 15 parts of D-mannitals, 10 ~ 20 parts of microcrystalline Cellulose, 0.5 ~ 1 part of magnesium stearate, 2 ~ 5 parts of hypromelloses, wherein, bitter gourd polypeptide, L-arabinose, inulin, plant sterol, D-mannital, microcrystalline Cellulose and magnesium stearate, after first crossing 100 mesh sieves respectively, put into three-dimensional mixer, after Rich chromium yeast, add three-dimensional mixer, by mix 20 ~ 30min in three-dimensional mixer, add hypromellose binding agent, granulate, 60 ~ 70 ℃ of dry 30min, granulate, tabletting obtains finished product.
Above-mentioned Rich chromium yeast adds three-dimensional mixer after diluting by times arching pushing.
The further scheme of the present invention is made up of following component, and each component is according to listed as parts by weight: 10 parts of bitter gourd polypeptides, 20 parts of L-arabinose, 0.2 part of Rich chromium yeast, 30 parts of inulin, 10 parts of plant sterols, 12 parts of D-mannitals, 15 parts of microcrystalline Cellulose, 0.7 part of magnesium stearate, 3 parts of hypromelloses, wherein, bitter gourd polypeptide, L-arabinose, inulin, plant sterol, D-mannital, microcrystalline Cellulose and magnesium stearate, first put into three-dimensional mixer after 100 mesh sieves respectively excessively; After Rich chromium yeast, add three-dimensional mixer; By mix 20 ~ 30min in three-dimensional mixer, add hypromellose binding agent, granulate, 60 ~ 70 ℃ of dry 30min, granulate, tabletting obtains composite sheet finished product.
The invention has the beneficial effects as follows: the present invention adopts multiple beneficial to make in the composition of glycemic control and blood lipid metabolism, compare and adopt separately bitter gourd polypeptide, inulin or plant sterol etc., better effects if after its combination, be of value to type 2 diabetes mellitus patient's glycemic control and blood lipid metabolism, and on liver, renal function without impact; In addition, the present invention can improve insulin sensitivity more, and can significantly reduce T-CHOL and the low-density lipoprotein cholesterol of patients with NIDDM.
The specific embodiment
Embodiment 1: the present invention is made up of following component, each component is according to listed as parts by weight:
8 parts of bitter gourd polypeptides, 15 parts of L-arabinose, 0.1 part of Rich chromium yeast, 25 parts of inulin, 5 parts of plant sterols, 10 parts of D-mannitals, 10 parts of microcrystalline Cellulose, 0.5 part of magnesium stearate, 2 parts of hypromelloses, wherein, bitter gourd polypeptide, L-arabinose, inulin, plant sterol, D-mannital, microcrystalline Cellulose and magnesium stearate, first put into three-dimensional mixer after 100 mesh sieves respectively excessively; After Rich chromium yeast, add three-dimensional mixer; By mix 20 ~ 30min in three-dimensional mixer, add hypromellose binding agent, granulate, 60 ~ 70 ℃ of dry 30min, granulate, tabletting obtains composite sheet finished product; Above-mentioned Rich chromium yeast adds three-dimensional mixer after diluting by times arching pushing, Rich chromium yeast not only has good blood sugar lowering, the effect of blood fat reducing, can also avoid the toxicity of inorganic chromate salt, regulate human body sugar, lipid and protein metabolism, be safely a kind of and efficient chromium supplement.
In view of Rich chromium yeast has unique nutrition and health care value, be not only directly developed to nutraceutical, also can further be prepared into multiple nutrients active substance, as the carrier of nutraceutical, further deep processing becomes the food that has more nutrition and health care value.The a collection of type-II diabetes patient who exceedes 10 years case histories is done to clinical trial, and these patients' blood glucose reduces significantly.
Wherein, inulin is of value to glycemic control and blood lipid metabolism, and inulin is the naturally occurring levan of occurring in nature (Fructans), is a kind of main carbohydrate deposit form in plant.Inulin-type levan (comprising inulin, oligofructose and polyfructosan) has been widely used in food industry as water soluble dietary fiber and prebiotics material.Inulin-type levan can digestedly not degraded at human body upper digestive tract, thereby not for intestinal absorption also intactly enters colon, under the effect of faecal flora, generate short-chain fatty acid, and then affect the concentration of circulation free fatty acid and there is the concentration of the gut hormone that regulates blood glucose effect, thereby improve blood sugar level.
Bitter gourd polypeptide is the bioactive ingredients extracting from fresh bitter melon seed plumule, is made up of 17 kinds of 166 aminoacid, have similar structure and physical and chemical index to islets of langerhans, has significant adjusting blood glucose effect.This result of study confirms by several scientists in succession, and this major scientific and technological achievement has obtained the approval in the world, and confirms through the clinical trial certificate of a large amount of domestic and foreign hospitals: bitter gourd polypeptide is entering human body onset after 30 minutes; It is 4-8 hours that the hypoglycemic persistent period falls in bitter gourd polypeptide; Bitter gourd polypeptide is particularly more outstanding in the effect of controlling post-prandial glycemia; It is lasting that hypoglycemic action effect falls in bitter gourd polypeptide, and hypoglycemia can't occur; The high-risk group of the applicable all kinds of diabetics of bitter gourd polypeptide and diabetes.
Bitter gourd polypeptide is a kind of pure natural plant ingredients, by activating insulin, activating Insulin receptor INSR, improves insulin effective rate of utilization and regulates blood glucose, thereby, realize the object that blood glucose is expressed according to the human normal physiology natural law, and be free from side effects.
Vegetable oil be content of phytosterol compared with one of food of horn of plenty, and wherein the content of phytosterol in Semen Maydis oil is higher.Character: this product is white powder, also can have ester shape to be dissolved in oils and fats.Pharmacological use: there is the medicine and health care such as katabolism that prevents coronary disease atherosclerosis, promotes cholesterol and be worth; Synthesis of vitamin d 3 important intermediate such as medicine such as class such as steroid such as grade.
The effect of D-mannital is: low calorie sweetener; The antitack agent of chewing gum and confection; Nutritional supplement and organize modifying agent; Wetting agent.
Microcrystalline Cellulose can be made important functional food ingredient in food industry, is a kind of desirable food supplement, and its effect having is: (1) keeps the stability of emulsifying and foam; (2) keep the stability (3) of high temperature to improve stability (4) supplementary and the thickening agent of liquid.
Magnesium stearate is the light fine powder without grittiness of white; Micro-have a special smell; There is soapy feeling with contact skin.This product is insoluble in water, ethanol or ether, mainly as lubricant, antiplastering aid, fluidizer.The granulation of suitable especially oils, extract medicament, the granule of making has good mobility and compressibility.In direct compression, be used as fluidizer.Also can be used as filter aid, clarifier and drip infusion, and the suspending agent of liquid preparation, thickening agent.
Hypromellose is the control speed polymeric material of slow releasing preparation; Can be used as stabilizing agent, suspending agent, tablet binder or tackifier.
Embodiment 2: the present invention is made up of following component, each component is according to listed as parts by weight:
15 parts of bitter gourd polypeptides, 25 parts of L-arabinose, 0.3 part of Rich chromium yeast, 35 parts of inulin, 15 parts of plant sterols, 15 parts of D-mannitals, 20 parts of microcrystalline Cellulose, 1 part of magnesium stearate, 5 parts of hypromelloses, wherein, bitter gourd polypeptide, L-arabinose, inulin, plant sterol, D-mannital, microcrystalline Cellulose and magnesium stearate, first put into three-dimensional mixer after 100 mesh sieves respectively excessively; After Rich chromium yeast, add three-dimensional mixer; By mix 20 ~ 30min in three-dimensional mixer, add hypromellose binding agent, granulate, 60 ~ 70 ℃ of dry 30min, granulate, tabletting obtains composite sheet finished product.
Embodiment 3: the present invention is made up of following component, each component is according to listed as parts by weight:
10 parts of bitter gourd polypeptides, 20 parts of L-arabinose, 0.2 part of Rich chromium yeast, 30 parts of inulin, 10 parts of plant sterols, 12 parts of D-mannitals, 15 parts of microcrystalline Cellulose, 0.7 part of magnesium stearate, 3 parts of hypromelloses, wherein, bitter gourd polypeptide, L-arabinose, inulin, plant sterol, D-mannital, microcrystalline Cellulose and magnesium stearate, first put into three-dimensional mixer after 100 mesh sieves respectively excessively; After Rich chromium yeast, add three-dimensional mixer; By mix 20 ~ 30min in three-dimensional mixer, add hypromellose binding agent, granulate, 60 ~ 70 ℃ of dry 30min, granulate, tabletting obtains composite sheet finished product.
The present invention adopts multiple beneficial to make in the composition of glycemic control and blood lipid metabolism, compare and adopt separately bitter gourd polypeptide, inulin or plant sterol etc., better effects if after its combination, is of value to type 2 diabetes mellitus patient's glycemic control and blood lipid metabolism, and on liver, renal function without impact; In addition, the present invention can improve insulin sensitivity more, and can significantly reduce T-CHOL and the low-density lipoprotein cholesterol of patients with NIDDM.
Composite sheet of the present invention shows through clinical test results: 4 weeks time, the FBG of composite sheet group of the present invention, HbA1c, HOMA-IR, T-CHOL (TC), low-density lipoprotein cholesterol (LDL) are compared the trend that has reduction with matched group; 8 weeks time, composite sheet group patient's FBG, HbA1c, HOMA-IR, TC, LDL compare remarkable reduction (P<0.05) with matched group, and all the other observation index are without significant change (P>0.05).Illustrate that with this composite sheet is of value to type 2 diabetes mellitus patient's glycemic control and blood lipid metabolism, and on liver, renal function without impact.
Insulin resistant is a key factor in type 2 diabetes mellitus pathogenesis; low insulin sensitivity is metabolism syndrome; comprise central obesity, dyslipidemia, hyperglycemia, hypertension and atherosclerotic basis; the metabolism of fatty acid is a principal element that determines to organize insulin sensitivity; fat abnormal stacking and lipolyse effect extremely can increase fatty acid by fatty tissue to non-fat tissue as skeletal muscle flow, this generation at insulin resistant and development in played very important effect.Epidemiologic data shows that the opposing of insulin may be relevant to the diet pattern of the minimizing of dietary fiber intake and high heat, studies confirm that the increase of dietary fiber intake can improve the sensitivity of insulin and have abroad.
There is dysbolism of blood fat in type 2 diabetes mellitus patient majority, wherein in blood, increasing of T-CHOL and low-density lipoprotein cholesterol is cardiovascular disease and atherosclerosis important risk factor, and the change of life style including Diet Therapy is the first-line treatment method of prevention and treatment hypercholesterolemia.
In clinical research, composite sheet experimenter of the present invention fasting glucose, glycolated hemoglobin, insulin resistance index in the time of 4 weeks are compared the trend that demonstrates reduction with matched group, and rear data were more obvious by 8 weeks.This time clinical experiment is reached a conclusion: composite sheet of the present invention has the dependent interaction that improves insulin sensitivity, and supplementary composite sheet can significantly reduce T-CHOL and the low-density lipoprotein cholesterol of patients with NIDDM.
Claims (3)
1. a manufacture method for Fructus Momordicae charantiae peptide arabinose composite sheet, is characterized in that being made up of following component, and each component is according to listed as parts by weight:
8 ~ 15 parts of bitter gourd polypeptides, 15 ~ 25 parts of L-arabinose, 0.1 ~ 0.3 part of Rich chromium yeast, 25 ~ 35 parts of inulin, 5 ~ 15 parts of plant sterols, 10 ~ 15 parts of D-mannitals, 10 ~ 20 parts of microcrystalline Cellulose, 0.5 ~ 1 part of magnesium stearate, 2 ~ 5 parts of hypromelloses, wherein, bitter gourd polypeptide, L-arabinose, inulin, plant sterol, D-mannital, microcrystalline Cellulose and magnesium stearate, first put into three-dimensional mixer after 100 mesh sieves respectively excessively; After Rich chromium yeast, add three-dimensional mixer; By mix 20 ~ 30min in three-dimensional mixer, add hypromellose binding agent, granulate, 60 ~ 70 ℃ of dry 30min, granulate, tabletting obtains finished product.
2. the manufacture method of Fructus Momordicae charantiae peptide arabinose composite sheet according to claim 1, is characterized in that: described Rich chromium yeast adds three-dimensional mixer after diluting by times arching pushing.
3. the manufacture method of Fructus Momordicae charantiae peptide arabinose composite sheet according to claim 1, is characterized in that, is further made up of following component, and each component is according to listed as parts by weight:
10 parts of bitter gourd polypeptides, 20 parts of L-arabinose, 0.2 part of Rich chromium yeast, 30 parts of inulin, 10 parts of plant sterols, 12 parts of D-mannitals, 15 parts of microcrystalline Cellulose, 0.7 part of magnesium stearate, 3 parts of hypromelloses, wherein, bitter gourd polypeptide, L-arabinose, inulin, plant sterol, D-mannital, microcrystalline Cellulose and magnesium stearate, first put into three-dimensional mixer after 100 mesh sieves respectively excessively; After Rich chromium yeast, add three-dimensional mixer; By mix 20 ~ 30min in three-dimensional mixer, add hypromellose binding agent, granulate, 60 ~ 70 ℃ of dry 30min, granulate, tabletting obtains composite sheet finished product.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410082006.8A CN103861086A (en) | 2014-03-07 | 2014-03-07 | Preparation method of bitter gourd peptide arabinose composite tablet |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410082006.8A CN103861086A (en) | 2014-03-07 | 2014-03-07 | Preparation method of bitter gourd peptide arabinose composite tablet |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103861086A true CN103861086A (en) | 2014-06-18 |
Family
ID=50900474
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410082006.8A Pending CN103861086A (en) | 2014-03-07 | 2014-03-07 | Preparation method of bitter gourd peptide arabinose composite tablet |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103861086A (en) |
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106421741A (en) * | 2016-09-26 | 2017-02-22 | 南京中生生物科技有限公司 | Water-soluble olive leaf extract health-care product and preparation method thereof |
| CN107198767A (en) * | 2017-05-19 | 2017-09-26 | 江苏江大五棵松生物科技有限公司 | It is a kind of to be used to prevent three high red yeast rice balsam pear complex peptides pieces |
| CN108478633A (en) * | 2018-04-27 | 2018-09-04 | 美益添生物医药(武汉)有限公司 | A kind of compound formulation improving insulin resistance and preparation method and application |
| CN109315574A (en) * | 2018-10-12 | 2019-02-12 | 肖文中 | A kind of mulberry leaf balsam pear pressed candy |
| WO2019058273A1 (en) | 2017-09-21 | 2019-03-28 | Anya Biopharm Inc. | Pharmaceutical compositions for delivery of peptide |
| CN110432500A (en) * | 2019-08-07 | 2019-11-12 | 武汉英纽林生物科技有限公司 | A kind of prebiotic compositions and preparation method and purposes containing inulin |
| CN110679943A (en) * | 2019-10-25 | 2020-01-14 | 李玉保 | Bitter gourd polypeptide compound nutrient with weight-losing and lipid-lowering effects and preparation method thereof |
| CN110694047A (en) * | 2019-10-25 | 2020-01-17 | 国众兴合生物医药科技有限公司 | Bitter gourd polypeptide compound botanical medicine for treating obesity and hyperlipidemia and preparation method thereof |
| CN110772630A (en) * | 2019-10-25 | 2020-02-11 | 运鸿集团股份有限公司 | Compound bitter gourd peptide oral liquid for activating insulin receptor and regulating blood sugar and preparation method thereof |
| CN110801024A (en) * | 2019-10-25 | 2020-02-18 | 运鸿集团股份有限公司 | Polysaccharide composite polypeptide for reducing blood sugar, blood fat and glycosylated hemoglobin and preparation method thereof |
-
2014
- 2014-03-07 CN CN201410082006.8A patent/CN103861086A/en active Pending
Cited By (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106421741A (en) * | 2016-09-26 | 2017-02-22 | 南京中生生物科技有限公司 | Water-soluble olive leaf extract health-care product and preparation method thereof |
| CN107198767A (en) * | 2017-05-19 | 2017-09-26 | 江苏江大五棵松生物科技有限公司 | It is a kind of to be used to prevent three high red yeast rice balsam pear complex peptides pieces |
| IL273451A (en) * | 2017-09-21 | 2020-05-31 | Anya Biopharm Inc | Pharmaceutical compositions for delivery of peptide |
| WO2019058273A1 (en) | 2017-09-21 | 2019-03-28 | Anya Biopharm Inc. | Pharmaceutical compositions for delivery of peptide |
| CN109843274A (en) * | 2017-09-21 | 2019-06-04 | 奥孟亚股份有限公司 | For delivering the pharmaceutical composition of victory peptide |
| IL273451B2 (en) * | 2017-09-21 | 2023-05-01 | Anya Biopharm Inc | Pharmaceutical compositions for delivery of peptide |
| JP2022132375A (en) * | 2017-09-21 | 2022-09-08 | アニヤ バイオファーム インク． | Pharmaceutical compositions for delivery of peptide |
| JP2021506731A (en) * | 2017-09-21 | 2021-02-22 | アニヤ バイオファーム インク． | Pharmaceutical composition for peptide delivery |
| EP3509573A4 (en) * | 2017-09-21 | 2020-04-29 | Anya Biopharm Inc. | Pharmaceutical compositions for delivery of peptide |
| CN108478633A (en) * | 2018-04-27 | 2018-09-04 | 美益添生物医药(武汉)有限公司 | A kind of compound formulation improving insulin resistance and preparation method and application |
| CN108478633B (en) * | 2018-04-27 | 2021-07-27 | 美益添生物医药(武汉)有限公司 | Compound preparation for improving insulin resistance and preparation method and application thereof |
| CN109315574A (en) * | 2018-10-12 | 2019-02-12 | 肖文中 | A kind of mulberry leaf balsam pear pressed candy |
| CN110432500A (en) * | 2019-08-07 | 2019-11-12 | 武汉英纽林生物科技有限公司 | A kind of prebiotic compositions and preparation method and purposes containing inulin |
| CN110801024A (en) * | 2019-10-25 | 2020-02-18 | 运鸿集团股份有限公司 | Polysaccharide composite polypeptide for reducing blood sugar, blood fat and glycosylated hemoglobin and preparation method thereof |
| CN110772630A (en) * | 2019-10-25 | 2020-02-11 | 运鸿集团股份有限公司 | Compound bitter gourd peptide oral liquid for activating insulin receptor and regulating blood sugar and preparation method thereof |
| CN110694047A (en) * | 2019-10-25 | 2020-01-17 | 国众兴合生物医药科技有限公司 | Bitter gourd polypeptide compound botanical medicine for treating obesity and hyperlipidemia and preparation method thereof |
| CN110679943A (en) * | 2019-10-25 | 2020-01-14 | 李玉保 | Bitter gourd polypeptide compound nutrient with weight-losing and lipid-lowering effects and preparation method thereof |
| GB2608697B (en) * | 2019-10-25 | 2023-11-15 | China Yunhong Holdings Co Ltd | Polysaccharide-peptide complex for lowering blood sugar, blood lipid and glycosylated hemoglobin levels, and preparation method |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103861086A (en) | Preparation method of bitter gourd peptide arabinose composite tablet | |
| CN101277710B (en) | Antiobesity composition | |
| Kochhar et al. | Effect of supplementation of traditional medicinal plants on blood glucose in non–insulin-dependent diabetics: A pilot study | |
| CN110447902B (en) | Composition with weight-losing effect | |
| CN101002906A (en) | Compounding traditional Chinese medicine, and its use | |
| CN106605822A (en) | Composition facilitating reducing of blood sugar and preparation method of composition | |
| CN102526479B (en) | Health-care medicine formula with functions of enhancing immunity and lowering blood sugar | |
| CN115120683A (en) | Raw material composition, traditional Chinese medicine fermentation product, preparation method and application thereof | |
| CN102526478A (en) | Formula of health-care medicine with functions of strengthening immunity and reducing blood sugar | |
| CN106362020B (en) | A kind of pine pollen composition and preparation method thereof with improvement defecating feces excretion | |
| CN100444746C (en) | A refined health food of high and cold mountain area crop and processing technology thereof | |
| CN106176953A (en) | A kind of Hyperglycemic health care compositions comprising leaf of Cyclocarya paliurus Iljinskaja, Fructus Momordicae and Folium Mori | |
| CN102551046A (en) | Natural health composition for weight reduction and application of same | |
| CN101946895A (en) | Functional food taking loach as main material and preparation method thereof | |
| CN101243883B (en) | Health food with function of reducing blood sugar and its preparation | |
| CN102813112B (en) | Foodstuff for diabetic nephropathy | |
| CN106177432A (en) | A kind of health composition comprising leaf of Cyclocarya paliurus Iljinskaja, Folium Mori, green tea and Rhizoma Polygonati Odorati | |
| CN106138282A (en) | A kind of refined even electuary and preparation method thereof for diabetes patient's regulating lipoid and reducing blood pressure | |
| CN110432492A (en) | A kind of hypoglycemic nano-clathrate and preparation method thereof | |
| CN1814214A (en) | Chinese medicine composition for treating body thin and delicate coustitution, and preparing method | |
| CN109771578A (en) | The composition for preventing and treating diabetes and complication | |
| CN104825821A (en) | Medicine for treating diabetes and preparation method thereof | |
| CN106177054A (en) | A kind of Hyperglycemic health care compositions comprising Cortex Mori and Pericarpium Citri Reticulatae | |
| CN101757499B (en) | Traditional Chinese medicine composite for treating impaired glucose tolerance | |
| CN103920140A (en) | Compound preparation for reducing blood glucose, body weight and fat for human |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20140618 |